23andMe selects TTAM as winning bidder for $305M in Chapter 11 sale, topping Regeneron

Chrome Holding Co.

TTAM Research Institute (affiliate of founder Anne Wojcicki) will acquire substantially all assets for $305M cash plus liability assumption.
Prior Regeneron asset purchase agreement ($256M) terminated; Regeneron remains backup bidder at $151M.
TTAM also to acquire telehealth business (Lemonaid Health) for $2.5M.
TTAM commits to privacy safeguards: customer data deletion rights, identity theft monitoring, privacy advisory board.
Court hearing on sale approval scheduled for June 17, 2025; closing expected in coming weeks.

item 1.01item 1.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.